Markus Lehmann

ORCID: 0009-0005-1964-197X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Shoulder and Clavicle Injuries
  • Trauma Management and Diagnosis
  • Lung Cancer Research Studies
  • Pancreatic and Hepatic Oncology Research
  • Shoulder Injury and Treatment
  • Cardiac Valve Diseases and Treatments
  • Cancer Genomics and Diagnostics
  • Tracheal and airway disorders
  • Airway Management and Intubation Techniques
  • Monoclonal and Polyclonal Antibodies Research
  • Hip disorders and treatments
  • Cancer Immunotherapy and Biomarkers
  • Lymphoma Diagnosis and Treatment
  • Infective Endocarditis Diagnosis and Management
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Radiopharmaceutical Chemistry and Applications
  • Thyroid Disorders and Treatments
  • Aortic Disease and Treatment Approaches
  • Gestational Trophoblastic Disease Studies
  • Myasthenia Gravis and Thymoma
  • Lung Cancer Treatments and Mutations
  • Peptidase Inhibition and Analysis
  • Cardiac tumors and thrombi
  • Occupational and environmental lung diseases
  • Congenital Diaphragmatic Hernia Studies

Universität Innsbruck
2023

Innsbruck Medical University
2023

Lungenklinik Hemer
2011-2019

University Medical Center of the Johannes Gutenberg University Mainz
2014

Johannes Gutenberg University Mainz
2014

Tilburg University
2001

Kantonsspital Baselland Standort Bruderholz
1991

Background: Cell-based bioassays for functional thyroid stimulating autoantibodies (TSAb) are sensitive diagnostic tools. However, there is no bioassay available that standardized with international reference material. We aimed to promote the standardization of test results among laboratories perform TSAb and calibrate levels against second standard (IS) 08/204 from National Institute Biological Standards Control (NIBSC). Methods: Serum activity was measured a FDA-cleared utilizes CHO cells...

10.1089/thy.2014.0346 article EN Thyroid 2014-10-15

Gestational trophoblastic neoplasia (GTN) including choriocarcinoma (CC) frequently requires multi-agent chemotherapy to achieve cure. In chemotherapy-resistant GTN, immunotherapy with the checkpoint inhibitors pembrolizumab, avelumab and camrelizumab are potential new treatment options previously described in small case series, phase 2 trials reports.A 32-year-old woman was diagnosed gestational (FIGO score 5). Prior administered therapy regimes included methotrexate, actinomycin-D followed...

10.1016/j.gore.2023.101259 article EN cc-by-nc-nd Gynecologic Oncology Reports 2023-08-12

8563 Background: Patient selection, dosing regimens and resistance mechanisms for immune checkpoint inhibitor combination therapy remain unmet medical needs in lung cancer. We present interim data from the small-cell cancer (SCLC) cohort of ongoing BIOLUMA trial which evaluates efficacy safety nivolumab ipilimumab with a broad translational program to identify potential biomarkers predictive response and/or including whole exome sequencing (WES) serial biopsies, functional analysis...

10.1200/jco.2019.37.15_suppl.8563 article EN Journal of Clinical Oncology 2019-05-20

In the course of a prospective study, CT arthrography was carried out on 40 patients with shoulder instability. 35 these lesion capsule and labrum demonstrated, indicating glenohumeral instability; in three this shown primarily by arthrography. patients, multidirectional instability demonstrated. four there an isolated labrum, whereas one patient all findings were normal. Compared capsulo-labral lesions, bone changes involving head humerus glenoid lesser importance, although their severity...

10.1055/s-2008-1033429 article EN RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 1990-11-01

Tracheal stenosis is a debilitating condition that often presents as an emergency and challenging to treat. Dilatation may avoid tracheostomy or costly tracheal resection reconstruction. Traditional dilators cause complete occlusion, preventing oxygenation ventilation, limiting the safe duration of dilatation, increasing risk hypoxic injury barotrauma. The study authors here assessed innovative nonocclusive dilatation balloon, which improve patient safety by allowing continuous gas...

10.1053/j.jvca.2022.02.004 article EN cc-by-nc-nd Journal of Cardiothoracic and Vascular Anesthesia 2022-02-12

e20550 Background: Patient selection, dosing regimens and resistance mechanisms for immune checkpoint inhibitor combination therapy remain unmet medical needs in lung cancer. Combining blockade of PD-1 CTLA-4 can be more effective than monotherapy but is accompanied by an increase toxicity. Thus, to circumvent unnecessary toxicity it great interest identify patients who will benefit from PD-1/PD-L1 alone add ipilimumab only case primary or secondary progression. We present interim data the...

10.1200/jco.2019.37.15_suppl.e20550 article EN Journal of Clinical Oncology 2019-05-20

25 Patienten, die sich einer nach M. Lange modifizierten Knochenspanplastik unterzogen, wurden einem durchschnittlichen postoperativen Intervall von 4 Jahren klinisch und CT-arthrographisch nachuntersucht. Reluxationen ventral traten postoperativ nicht mehr auf. Bezüglich des Nachweises residueller ventraler Instabilitäten ergab bei 20/25 Patienten (80 %) eine Befundkorrelation zwischen CT-Arthrographie klinischer Untersuchung. Neu aufgetretene oder verbliebene dorsale durch den Nachweis...

10.1055/s-2008-1033267 article DE RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 1991-10-01

Marginalzonen-Lymphome (MZoL) gehören nach WHO-Klassifikation 2008 der Non-Hodgkin-Lymphome (NHL) zu den indolenten, selteneren, langsam wachsenden NHL. Extranodale Marginalzonen-Lymphom (eMZoL), finden sich im Gastrointestinaltrakt 50%, aber auch in Lunge mit 14% und anderen Organen. Die Diagnostik bronchialen oder pulmonalen seltenen Marginalzonen-Lymphomen erfolgt Regel über Pneumologen.

10.1055/s-0037-1598276 article DE Pneumologie 2017-02-23
Coming Soon ...